{"title":"Longitudinal and cross-sectional study of Chlamydia serpentis in captive snakes: Insights from two successive outbreaks in a zoological institution","authors":"Huberdeau Pierre , Aaziz Rachid , Jouvion Gregory , Laidebeure Sylvie , Borel Nicole , Lécu Alexis , Laroucau Karine","doi":"10.1016/j.vetmic.2025.110648","DOIUrl":null,"url":null,"abstract":"<div><div>Among the <em>Chlamydia</em> species known to infect snakes, <em>C. serpentis</em> is a recently described pathogen. A first outbreak of <em>C. serpentis</em> in the snake collection of a zoological institution was documented in 2018. In 2023, a wild-caught asp viper (<em>Vipera aspis</em>) tested positive by PCR for <em>C. serpentis</em>, following introduction with two snakes of the same species that had tested positive in 2018. Real-time PCR analysis was used to detect the presence of <em>C. serpentis</em> in oral/cloacal swabs and tissue samples from snakes, and environmental samples from the terrariums of confirmed infected individuals. A sequential screening of 29 snakes was performed based on disease-risk analysis, with 5/29 (17.2 %) testing positive, including the three asp vipers and two co-housed European long-nosed vipers (<em>Vipera ammodytes</em>), all belonging to the same epidemiological unit. All three snakes treated with 5 mg/kg marbofloxacin intramuscularly daily tested PCR negative following treatment. Comparison of the <em>omp</em>A sequences and MLST profiles of the strains involved in the 2018 and 2023 outbreaks suggests a single source of contamination and unique circulating strain. As in 2018, the origin of the infection remains unknown, but potential sources include persistent infection and/or intermittent shedding among infected snakes from the 2018 outbreak, environmental persistence, or introduction via the newly acquired wild-caught viper. These successive outbreaks provide insights into the epidemiology and dynamics of <em>C. serpentis</em> infections in captive snakes, further supporting the need for integrated management strategies combining medical treatment, environmental decontamination, and epidemiological unit management to minimize cross-contamination and prevent pathogen transmission.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"308 ","pages":"Article 110648"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113525002834","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Among the Chlamydia species known to infect snakes, C. serpentis is a recently described pathogen. A first outbreak of C. serpentis in the snake collection of a zoological institution was documented in 2018. In 2023, a wild-caught asp viper (Vipera aspis) tested positive by PCR for C. serpentis, following introduction with two snakes of the same species that had tested positive in 2018. Real-time PCR analysis was used to detect the presence of C. serpentis in oral/cloacal swabs and tissue samples from snakes, and environmental samples from the terrariums of confirmed infected individuals. A sequential screening of 29 snakes was performed based on disease-risk analysis, with 5/29 (17.2 %) testing positive, including the three asp vipers and two co-housed European long-nosed vipers (Vipera ammodytes), all belonging to the same epidemiological unit. All three snakes treated with 5 mg/kg marbofloxacin intramuscularly daily tested PCR negative following treatment. Comparison of the ompA sequences and MLST profiles of the strains involved in the 2018 and 2023 outbreaks suggests a single source of contamination and unique circulating strain. As in 2018, the origin of the infection remains unknown, but potential sources include persistent infection and/or intermittent shedding among infected snakes from the 2018 outbreak, environmental persistence, or introduction via the newly acquired wild-caught viper. These successive outbreaks provide insights into the epidemiology and dynamics of C. serpentis infections in captive snakes, further supporting the need for integrated management strategies combining medical treatment, environmental decontamination, and epidemiological unit management to minimize cross-contamination and prevent pathogen transmission.
期刊介绍:
Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal.
Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge.
Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.